CR20200552A - Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe - Google Patents

Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe

Info

Publication number
CR20200552A
CR20200552A CR20200552A CR20200552A CR20200552A CR 20200552 A CR20200552 A CR 20200552A CR 20200552 A CR20200552 A CR 20200552A CR 20200552 A CR20200552 A CR 20200552A CR 20200552 A CR20200552 A CR 20200552A
Authority
CR
Costa Rica
Prior art keywords
soft gel
cold
gel capsule
flu
high concentration
Prior art date
Application number
CR20200552A
Other languages
English (en)
Inventor
Pineiro Maria Elena Iglesias
Reinhard Walter
Perez Javier Zumeta
Saiz Maria Pilar Sanz
Maluenda Blanca Alvarez
Anthony Bell
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CR20200552A publication Critical patent/CR20200552A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación proporciona formulaciones farmacéuticas en suspensión para medicamentos para el resfriado y la gripe, específicamente formulaciones para suspensiones y formas de dosificación de cápsulas de gel blandas que tienen un tamaño reducido. La presente divulgación también proporciona métodos para preparar las suspensiones y formas de dosificación de cápsulas de gel blanda.
CR20200552A 2018-05-16 2019-05-13 Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe CR20200552A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862672457P 2018-05-16 2018-05-16
US201962816727P 2019-03-11 2019-03-11
PCT/US2019/032017 WO2019222100A1 (en) 2018-05-16 2019-05-13 High concentration suspension formulation for cold and flu soft gel capsule medications

Publications (1)

Publication Number Publication Date
CR20200552A true CR20200552A (es) 2021-05-13

Family

ID=66690971

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200552A CR20200552A (es) 2018-05-16 2019-05-13 Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe

Country Status (7)

Country Link
US (2) US11911517B2 (es)
EP (1) EP3793535A1 (es)
CA (1) CA3100314A1 (es)
CR (1) CR20200552A (es)
MX (2) MX2020012233A (es)
NI (1) NI202000082A (es)
WO (1) WO2019222100A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240058274A1 (en) * 2021-01-11 2024-02-22 Bayer Healthcare Llc Concentrated liquid gel formulations containing naproxen salts

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115315A (en) * 1977-02-16 1978-09-19 Ncr Corporation Pearlescent capsules and process for their preparation
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
WO1985003439A1 (en) * 1984-02-08 1985-08-15 R.P. Scherer Corporation Acetaminophen gelatin capsule providing rapid onset of therapeutic activity upon oral administration
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
NZ256346A (en) 1992-10-09 1997-04-24 Procter & Gamble Medicaments containing 3-l-menthoxypropane-1,2-diol for treating cold symptoms
US5505961A (en) 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
US5510389A (en) 1994-03-02 1996-04-23 The Procter & Gamble Company Concentrated acetaminophen solution compositions
CA2223768A1 (en) * 1995-06-09 1996-12-27 R.P. Scherer Corporation Suspension and soft gelatin capsules containing particulate matter
US6287985B1 (en) 1995-10-27 2001-09-11 Honeywell International Inc. Process for applying a molten droplet coating for integrated circuits
US5759579A (en) 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
US6221391B1 (en) 1998-11-23 2001-04-24 Accucaps Industries Limited Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
US6846495B2 (en) 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
US7029698B2 (en) 2001-11-21 2006-04-18 R.P. Scherer Technologies, Inc. Acetaminophen compositions
US20040162273A1 (en) 2003-01-23 2004-08-19 The Procter & Gamble Company Powder pharmaceutical compositions
JP2006514119A (ja) 2003-02-12 2006-04-27 アール アンド ピー コリア カンパニー リミテッド 溶解率が向上した難溶性薬剤の溶媒系
US20050249802A1 (en) 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US20070254027A1 (en) 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20080014275A1 (en) 2006-07-13 2008-01-17 Buehler Gail K Pharmaceutical suspensions and related methods
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110020440A1 (en) 2007-11-19 2011-01-27 Cadila Pharmaceuticals Limited Stable solutions of sparingly soluble actives
US8518439B2 (en) 2008-12-03 2013-08-27 Novartis Ag Liquid therapeutic composition
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
US10987365B2 (en) 2012-10-01 2021-04-27 Gm Pharmaceuticals, Inc. Compositions and methods for the treatment of pain
JP6067892B2 (ja) 2013-02-28 2017-01-25 ファイザー・インク 安定性を増強した新規な液体組成物
CN103463088B (zh) * 2013-08-16 2015-10-28 安士制药（中山）有限公司 一种日用治疗感冒的组合物及软胶囊
US9504656B2 (en) 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients
WO2016044805A1 (en) * 2014-09-18 2016-03-24 Virun, Inc. Soft gel compositions and pre-gel concentrates
WO2016084099A1 (en) * 2014-11-25 2016-06-02 Biological E Limited Soft gelatin capsule composition of anti-tussive agents
US20180071221A1 (en) 2015-03-02 2018-03-15 Bionpharma Healthcare Llc Immediate release soluble ibuprofen compositions
ES2972665T3 (es) 2015-03-26 2024-06-13 Patheon Softgels Inc Cápsulas liquisoft
US20180263916A1 (en) 2015-09-28 2018-09-20 Puracap Pharmaceutical Llc Soft gelatin capsules containing a mixture of analgesics and decongestants, expectorants, antitussives and/or antihistamines
US20170095736A1 (en) 2015-10-06 2017-04-06 Giovanni Maria Giro SYSTEM, METHOD, and COMPUTER PROGRAM FOR PROVIDING A TIME BASED MEDIA CONTEST PLATFORM
WO2018183082A1 (en) 2017-03-27 2018-10-04 Paracap Pharmaceutical Llc Formulations containing expectorants or decongestants

Also Published As

Publication number Publication date
WO2019222100A1 (en) 2019-11-21
NI202000082A (es) 2021-03-11
MX2024012987A (es) 2024-11-08
US20190350865A1 (en) 2019-11-21
EP3793535A1 (en) 2021-03-24
CA3100314A1 (en) 2019-11-21
US11911517B2 (en) 2024-02-27
US20240165039A1 (en) 2024-05-23
MX2020012233A (es) 2021-01-29

Similar Documents

Publication Publication Date Title
JOP20240115B1 (ar) صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
MX2025001906A (es) Construcciones de anticuerpos anti-ror
CR20210281A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
EP4233892A3 (en) Stable anti-ifnar1 formulation
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
PH12021551916A1 (en) Therapeutic antibody formulation.
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
NZ702342A (en) Pharmaceutical formulation
PH12022551468A1 (en) Compounds active towards nuclear receptors
WO2021118930A3 (en) Anti-pd-l1 antibody formulations
MX2025000572A (es) Formulaciones de capsula de cubierta blanda y metodos de preparacion y uso de las mismas
MX2020005373A (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis.
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
BR112021014566A2 (pt) Moduladores de gpr35
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
MX2020012233A (es) Formula de suspension de alta concentracion para medicamentos en capsula de gel blanda para resfriado y gripe.
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
PH12018502139A1 (en) Phosphaplatin liquid formulations
MX2020000009A (es) Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos.
MX393915B (es) Nuevas formulaciones orales de belinostat.